Comparison of Efficacy of Ultrasound-Guided Steroid Injection and Dry Needling in Piriformis Muscle Syndrome
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Primary Endpoint
- Visual Analog Scale (VAS) (Resting)
Study Overview
Brief Summary
The aim of this study is to to compare its effectiveness ultrasound-guided steroid injection, dry needling treatments and exercises in patients diagnosed with piriformis syndrome.
Detailed Description
Piriformis syndrome is a painful entrapment neuropathy caused by compression of the sciatic nerve under the piriformis muscle. The most common cause is myofascial pain syndrome. There is no gold standard treatment for piriformis syndrome. The main purpose of treatment methods is to reduce local pain, muscle tension and spasm. This work; it will contribute to the literature by comparing steroid, dry needling and exercise treatments in patients with piriformis syndrome.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Masking Description
Outcome measures will be evaluated by an independent physiatrist, blinded for the assigned treatment.
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age between 18-60,
- •Hip pain for ≥1 month
- •Local piriformis pain with prolonged sitting (>20 minutes) and increased sensitivity
- •Patients with suspected piriformis syndrome based on clinical maneuvers
- •Signing and informed consent from showing consent to participate in the study
Exclusion Criteria
- •Hip surgery
- •Lumbar disc disease
- •History of inflammatory hip disease
- •Medical treatment for pain is started
- •Neurological deficit
- •Breastfeeding or pregnant
- •Allergy to local anesthetic
- •Use of anticoagulants
- •Body mass index >35
- •Active psychiatric illness
- •Uncontrolled hypertension and diabetes mellitus disease
- •Noncompensated chronic lung/heart/renal failure
- •History of vascular/tumoral disease
Outcomes
Primary Outcomes
Visual Analog Scale (VAS) (Resting)
Time Frame: at baseline and change from baseline VAS (resting) at 4 weeks and 12 weeks
Average hip pain intensity at rest over the past week is a visual analog scale. (VAS; ranging from 0 to 10, 0 = no pain and 10 = worst possible pain)
Visual Analogue Scale (VAS) (Sitting)
Time Frame: at baseline and change from baseline VAS (sitting) at 4 weeks and 12 weeks
Average hip pain intensity in a sitting position over the past 24 hours, a visual analog scale. (VAS; ranging from 0 to 10, 0 = no pain and 10 = worst possible pain)
Visual Analog Scale (VAS) (Movement)
Time Frame: at baseline and change from baseline VAS (movement) at 4 weeks and 12 weeks
Average hip pain intensity during movement over the past 1 week is a visual analog scale. (VAS; ranging from 0 to 10, 0 = no pain and 10 = worst possible pain)
Secondary Outcomes
- Oswestry disability index (ODI)(at baseline and change from baseline ODI at 4 weeks and 12 weeks)
Investigators
Yasin Demir
Associate Professor
Gaziler Physical Medicine and Rehabilitation Education and Research Hospital